Inflammasome Genes’ Polymorphisms in Egyptian Chronic Hepatitis C Patients: Influence on Vulnerability to Infection and Response to Treatment
Table 3
Relation of Allele and genotype frequencies of SNPs with the HCV susceptibility.
Gene
SNP ID
P N (%)
C N (%)
OR
95% CI
value
NLRP3
rs1539019
AA
60 (29.9%)
31 (32.6%)
0.88
0.52-1.5
0.63
AC
120 (59.7%)
39 (41.1%)
2.13
1.3-3.5
0.003
CC
21 (10.4%)
25 (26.3%)
0.33
0.17-0.62
0.0006
A
104 (59.7%)
51 (53.2%)
1
0.64-1.68
0.87
C
96 (40.3%)
49 (46.8%)
0.96
0.59-1.55
0.87
rs35829419
CC
173 (86.1%)
48 (50.5%)
6.05
3.4-10.66
<0.0001
CA
27 (13.4%)
44 (46.3%)
0.18
0.1-0.32
<0.0001
AA
1 (0.5%)
3 (3.2%)
0.15
0.016-1.5
0.11
C
373 (92.8%)
140 (73.7%)
4.59
2.79-7.55
<0.0001
A
29 (7.2%)
50 (26.3%)
0.22
0.13-0.36
<0.0001
rs10754558
GG
39 (26.5%)
25 (31.7%)
0.78
0.43-1.42
0.42
GC
78 (53.1%)
34 (43%)
1.5
0.86-2.6
0.15
CC
30 (20.4%)
20 (25.3%)
0.76
0.4-1.44
0.4
G
156 (53.1%)
84 (53.2%)
1
0.68-1.47
0.98
C
138 (46.9%)
74 (46.8%)
1
0.68-1.48
0.98
IL-1β
rs1143629
AA
86 (42.8%)
29 (30.5%)
1.7
1-2.86
0.04
AG
84 (41.8%)
50 (52.6%)
0.65
0.4-1.1
0.08
GG
31 (15.4%)
16 (16.8%)
0.9
0.47-1.74
0.76
A
256 (63.7%)
108 (56.8%)
1.33
0.94-1.9
0.11
G
146 (36.3%)
82 (43.2%)
0.75
0.53-1.1
0.11
rs1143634
GG
97 (48.3%)
47 (49.5%)
0.95
0.58-1.55
0.85
GA
85 (42.3%)
33 (34.7%)
1.38
0.83-2.3
0.22
AA
19 (9.5%)
15 (15.8%)
0.56
0.27-1.15
0.11
G
279 (69.4%)
127 (66.8%)
1.13
0.78-1.63
0.53
A
123 (30.6%)
63 (33.2%)
0.89
0.61-1.29
0.53
IL-18
rs187238
CC
102 (50.7%)
52 (54.7%)
0.85
0.52-1.39
0.52
CG
94 (46.8%)
36 (37.9%)
1.44
0.87-2.37
0.15
GG
5 (2.5%)
7 (7.4%)
0.32
0.1-1.04
0.058
C
298 (74.1%)
140 (73.7%)
1.02
0.69-1.52
0.91
G
104 (25.9%)
50 (26.3%)
0.98
0.66-1.45
0.91
rs1946518
GG
70 (34.8%)
47 (49.5%)
0.55
0.33-0.9
0.017
GT
92 (45.8%)
37 (38.9%)
1.32
0.8-2.17
0.27
TT
39 (19.4%)
11 (11.6%)
1.84
0.9-3.77
0.097
G
232 (57.7%)
131 (69%)
0.61
0.43-0.89
0.009
T
170 (42.3%)
59 (31%)
1.63
1.13-2.34
0.009
CARD8
rs6509365
AA
74 (36.8%)
44 (46.3%)
0.68
0.41-1.1
0.12
AG
98 (48.8%)
40 (42.1%)
1.31
0.8-2.14
0.28
GG
29 (14.4%)
11 (11.6%)
1.29
0.61-2.7
0.5
A
246 (61.2%)
128 (67.4%)
0.76
0.53-1.1
0.15
G
156 (38.8%)
62 (32.6%)
1.31
0.91-1.8
0.15
rs2043211
AA
82 (40.8%)
47 (49.5%)
0.7
0.43-1.15
0.16
AT
94 (46.8%)
33 (34.7%)
1.65
1-2.73
0.05
TT
25 (12.4%)
15 (15.8%)
0.76
0.38-1.51
0.43
A
258 (64.2%)
127 (66.8%)
0.89
0.62-1.28
0.53
T
144 (35.8%)
63 (33.2%)
1.13
0.78-1.62
0.53
IFN = interferon; OR = odds ratio; CI = confidence interval; C = healthy control, P = HCV patients, SVR = sustained virological response, NR = nonresponder. All SNPs were characterized for 201 HCV patients (except rs10754558 is performed only on 147 patients) and 95 controls. Significant values are in italics. is considered significant.
